Non-GAAP Gross Profit -- $57.3 million for the quarter, up 16% year over year; full year non-GAAP gross profit of $180.3 million increased by 4%. Adjusted EBITDA -- $17.7 million for the quarter at an ...

On today's call, we would like to cover three topics. Revenue growth of 31% is our strongest annual increase since 2021, and our full-year 20% EBITDA margin is our highest annual margin. Second, both ...

Background Data-sharing mandates from funders and journals have increased in recent years, but little is known about how shared data are used. Existing research has focused on access frameworks, with ...

The nonsteroidal mineralocorticoid receptor antagonist finerenone has been reported to improve kidney and cardiovascular outcomes in persons with type 2 diabetes and chronic kidney disease (CKD).

The Therapeutic Goods Administration (TGA) is Australia's regulator of medicines, medical devices and biologicals. The TGA assesses therapeutic goods ...